Celanese Corporation

▲ Bull Case

• ◆Acetyl chain structurally undervalued. CE's acetyl segment alone, at normalized mid-cycle margins (~22-25% EBIT) and 7-8x EBITDA, justifies $40-50/share of equity value — close to the entire current market cap. The Engineered Materials segment is therefore essentially being given away.
• ◆Leverage as feature, not bug. At 5.5x current leverage, each 1% improvement in EBITDA translates to ~5-6% improvement in equity value. The base-case EBITDA recovery of ~30% from FY24 trough to FY28 normalized maps to 150%+ equity appreciation without any multiple expansion.
• ◆Specialty chemicals sector re-rating tailwind. Specialty chemicals sector trades at ~11x median EV/EBITDA H1 2025; CE at ~7-7.5x reflects a 3-4x discount almost entirely attributable to leverage. As CE leverage normalizes to 3x by 2027, peer-discount should narrow to 1-1.5x, implying $150+/share at base-case EBITDA.

▼ Bear Case

• ◆European auto could decline further. European automotive production faces structural EV transition costs, Chinese OEM competition, and energy disadvantages. Every additional 5% decline in European auto = ~$100-150M EM revenue headwind, which delays the deleveraging timeline by 6-12 months and could trigger an outlook downgrade from S&P.
• ◆Synergy underdelivery threatens credibility. If the $450M synergy target finishes at $350-400M, the cumulative $50-100M EBITDA gap reduces FCF by ~$70M/year, extends deleveraging by 1+ year, and adds permanent compression to the M&M acquisition thesis.
• ◆Acetyl pricing trough may persist. Chinese coal-based acetic acid overcapacity could keep Asian reference pricing below $500/MT through 2027, compressing Acetyl Chain EBIT margins from ~20% to ~15% and removing one of the three pillars of the EBITDA recovery story.

“Consensus sees CE as a 'levered cyclical that made a poorly-timed acquisition; wait for deleveraging.' This produces a compressed multiple (6.5-7.5x forward EV/EBITDA) and an EPS expectation that has been revised down materially since 2024 — current consensus FY26 EPS $5.62 vs. our base case $9.52. The Street breaks into three camps: (1) Bears argue European auto is structurally smaller, M&M was overpaid, and the deleveraging timeline is at risk. (2) Cautious neutrals acknowledge dividend yield and FCF but want to see clear EBITDA recovery before re-rating. (3) Constructive longs recognize the asymmetric setup but anchor on near-term earnings, not normalized power. Our base case is materially above consensus on FY26-27 EPS. The market is debating whether 2026 EBITDA recovers to $2.0B or to $2.3B; we model $2.3B; the disagreement value is ~$25-35/share.”

• ◆Q3 2026 — Synergy program completion announcement (~$450M captured run-rate). Triggers re-rating as integration overhang lifts.
• ◆2026-2027 — Credit rating action. S&P/Moody's confirming IG or potentially upgrading to BBB-stable as leverage hits 3.5x.
• ◆2027 — Buyback resumption. First meaningful buyback program since November 2022 close. Signals balance sheet health restored.
• ◆2026-2027 — Major EV platform win disclosure. CE qualifying on Tesla/BYD/European EV platforms; multi-year platform wins lock in EM volume.
• ◆2025-2026 — Non-core asset divestiture. Management signaled willingness to divest >$500M of M&M-acquired commodity nylon grades to accelerate deleveraging.
• ◆Acetic acid pricing inflection. Asian reference pricing crossing $600/MT signals mid-cycle resumption — leading indicator for acetyl chain EBITDA recovery.

• ◆Credit rating downgrade to BB+ (high yield). $200-300M/year added interest cost; triggers forced selling by IG-mandated investors; potential covenant tests.
• ◆Dividend cut. $315M/yr dividend is ~30-40% of FCF; further EBITDA deterioration of 15-20% could force a cut. Signal effect would be -15-20% on equity immediately.
• ◆European auto further decline. Largest near-term volume headwind; structural EV-transition issues could persist multiple years.
• ◆China acetyl overcapacity surge. Renewed Chinese capacity additions or weak domestic demand could trigger export surges that compress global pricing.
• ◆Synergy underdelivery. $50-100M gap to $450M target would extend deleveraging timeline 12-18 months.
• ◆CEO succession risk. Lori Ryerkerk has owned the M&M story; no public succession plan. Departure mid-integration would be a significant negative catalyst.